Stockreport

Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]

Prelude Therapeutics Incorporated  (PRLD) 
PDF Initiated a Phase 1 trial for PRT7732, its first-in-class oral SMARCA2 degrader in patients with SMARCA4-mutated cancers Presented first preclinical data from its nex [Read more]